

NCIC CLINICAL TRIALS GROUP

**INVESTIGATIONAL NEW DRUG COMMITTEE**

DISEASE SITE COMMITTEE MEETING OPEN AGENDA

Friday, May 2, 2008 ~ 10.30 – 3.00  
Delta Chelsea Hotel, Toronto / Room: Churchill

Chair: Karen Gelmon

---

10.30am	Welcome		Karen Gelmon
10.35am	PI3 kinase inhibitors: update		Janet Dancey
11.00am (15 mins each)	Completed – Ph 1 Phase II	IND 166b IND.163 Biomarkers IND.160b	Gerry Batist Susan Ellard Amit Oza
12.00-12.30	Box Lunch / Break		
12.30	Report on phase I and II design from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT)		Chris Booth
13.00	Ongoing – Ph 1	IND.162 IND.173 IND.175 (CRC) IND.177 IND.179 IND.181 IND.186 IND. 188	Warren Mason Malcolm Moore Eric Chen Eric Chen Amit Oza Susan Dent David Macdonald Lillian Siu
	Ongoing – Ph II	IND.182 IND.183 IND.184 IND.185 IND.189	Rena Buckstein Scott Laurie Helen Mackay Jim Biagi Teresa Petrella
14.30	Planned	IND.190 IND.191 IND.192 IND. 178	Seymour / Eisenhower Seymour / Eisenhower Seymour / Eisenhower Seymour / Eisenhower
14.55	Close		Hal Hirte

Final